Geneva - Pharmaceutical companies are investigating the effectiveness of four possible vaccines and some 30 medicines are being tested to counteract the deadly effects of Covid-19, according to a report issued on Monday by the press.
The International Federations of the Pharmaceutical Manufacturers and Associations (IFPMA), the European (EFPIA) and the American (PHRMA) along with the Korean Research based- Pharmaceutical Industry Association (KRPIA) reported that since the new coronavirus' existence was confirmed and evidenced its deadly effect and speed of spreading they have been investigating a possible treatment to counteract the epidemic.
Among the likely candidates' solutions are antiviral drugs previously tested in pathogens such as Ebola and Acquired Immunodeficiency Virus.
Another research line includes protease inhibitors or ACE immunotherapeutic drugs (angiotensin-converting enzyme), whose activity has been found relevant to cope with the new coronavirus.
In the group of 30 meds stand out treatments that combine antiretroviral drugs lopinavir and ritonavir, remdesivir, zanamivir inhibitor or interferon.
Meanwhile, the Japanese company Takeda began the development of a drug derived from blood plasma, polyclonal hyperimmune globulin, to treat high-risk individuals with Covid-19.
While other companies, such as PFIZER, announced a preliminary evaluation of certain antiviral compounds that were under development and inhibited the replication of coronaviruses similar to that caused by Covid-19 in cultured cells.
With the same purpose, Regeneron Pharmaceuticals joined the United States Department of Health and Human Services and other laboratories in different nations focus their efforts to create a vaccine that neutralizes the virus.
The general director of the International Federation of the Pharmaceutical Industry, Thomas Cueni said that sharing the Covid-19 genome allowed researchers to quickly start the early stages of research and development.
WHO's Director General Tedros Adhanom Ghebreyesus expressed that the coordination and complementation of the different research teams is vital in order to offer the best pieces of advice, and at the same time the countries make decisions based on life-saving evidence.